Published in J Gastroenterol on May 01, 2005
Regulation of inflammation by short chain fatty acids. Nutrients (2011) 2.15
Novel pathophysiological concepts of inflammatory bowel disease. J Gastroenterol (2006) 1.46
Epithelial expression of interleukin-37b in inflammatory bowel disease. Clin Exp Immunol (2013) 1.28
Inflammatory responses induced by interleukin-17 family members in human colonic subepithelial myofibroblasts. J Gastroenterol (2007) 1.07
Post-translational inhibition of IP-10 secretion in IEC by probiotic bacteria: impact on chronic inflammation. PLoS One (2009) 0.99
The production of interferon-gamma-inducible protein 10 by granulocytes and monocytes is associated with ulcerative colitis disease activity. J Gastroenterol (2007) 0.91
Cellobiose Prevents the Development of Dextran Sulfate Sodium (DSS)-Induced Experimental Colitis. J Clin Biochem Nutr (2010) 0.82
Interaction between interleukin-17-producing CD4+ T cells and colonic subepithelial myofibroblasts: what are they doing in mucosal inflammation? J Gastroenterol (2007) 0.81
Inhibitory effects of short-chain fatty acids on matrix metalloproteinase secretion from human colonic subepithelial myofibroblasts. Dig Dis Sci (2008) 0.81
The Role of the Microbial Metabolites Including Tryptophan Catabolites and Short Chain Fatty Acids in the Pathophysiology of Immune-Inflammatory and Neuroimmune Disease. Mol Neurobiol (2016) 0.80
Factors Influencing the Gut Microbiota, Inflammation, and Type 2 Diabetes. J Nutr (2017) 0.77
IP10 released by colonic subepithelial myofibroblasts: by which stimuli and for which tissue? J Gastroenterol (2005) 0.75
IL-22 ameliorates intestinal inflammation in a mouse model of ulcerative colitis. J Clin Invest (2008) 6.17
Interleukin-22, a member of the IL-10 subfamily, induces inflammatory responses in colonic subepithelial myofibroblasts. Gastroenterology (2005) 3.65
Neutralization of interleukin-17 aggravates dextran sulfate sodium-induced colitis in mice. Clin Immunol (2004) 3.41
Curcumin maintenance therapy for ulcerative colitis: randomized, multicenter, double-blind, placebo-controlled trial. Clin Gastroenterol Hepatol (2006) 3.01
A pilot randomized trial of a human anti-interleukin-6 receptor monoclonal antibody in active Crohn's disease. Gastroenterology (2004) 2.75
Evidence-based clinical practice guidelines for irritable bowel syndrome. J Gastroenterol (2014) 2.30
Decreased abundance of Faecalibacterium prausnitzii in the gut microbiota of Crohn's disease. J Gastroenterol Hepatol (2013) 1.80
IL-17 stimulates inflammatory responses via NF-kappaB and MAP kinase pathways in human colonic myofibroblasts. Am J Physiol Gastrointest Liver Physiol (2002) 1.64
Increased aggregation response of platelets in patients with inflammatory bowel disease. J Gastroenterol (2006) 1.59
Interleukin-33 expression is specifically enhanced in inflamed mucosa of ulcerative colitis. J Gastroenterol (2010) 1.58
Matrix metalloproteinase-3 secretion from human colonic subepithelial myofibroblasts: role of interleukin-17. J Gastroenterol (2003) 1.55
Interleukin-17 augments tumor necrosis factor-alpha-induced granulocyte and granulocyte/macrophage colony-stimulating factor release from human colonic myofibroblasts. J Gastroenterol (2005) 1.54
Germinated barley foodstuff, a prebiotic product, ameliorates inflammation of colitis through modulation of the enteric environment. J Gastroenterol (2003) 1.51
Suppression of interleukin-1beta- and tumor necrosis factor-alpha-induced inflammatory responses by leukocytapheresis therapy in patients with ulcerative colitis. J Gastroenterol (2004) 1.46
Monitoring 6-thioguanine nucleotide concentrations in Japanese patients with inflammatory bowel disease. J Gastroenterol Hepatol (2008) 1.43
Prebiotic treatment in experimental colitis reduces the risk of colitic cancer. J Gastroenterol Hepatol (2011) 1.43
Immunohistochemical analysis of cell cycle-regulating-protein (p21, p27, and Ki-67) expression in gastroesophageal reflux disease. J Gastroenterol (2002) 1.42
Luminal polyamines upregulate transmural glucose transport in the rat small intestine. J Gastroenterol (2002) 1.39
IL-6 secretion by human pancreatic periacinar myofibroblasts in response to inflammatory mediators. J Immunol (2002) 1.38
Novel biodegradable stents for benign esophageal strictures following endoscopic submucosal dissection. Dig Dis Sci (2007) 1.37
Multicenter analysis of fecal microbiota profiles in Japanese patients with Crohn's disease. J Gastroenterol (2012) 1.31
Treatment of ulcerative colitis by feeding with germinated barley foodstuff: first report of a multicenter open control trial. J Gastroenterol (2002) 1.30
Fecal calprotectin is a useful marker for disease activity in pediatric patients with inflammatory bowel disease. Dig Dis Sci (2011) 1.30
Increased apoptosis and decreased proliferation of colonic epithelium in dextran sulfate sodium-induced colitis in mice. Oncol Rep (2010) 1.27
Role of intestinal subepithelial myofibroblasts in inflammation and regenerative response in the gut. Pharmacol Ther (2007) 1.26
An open-label prospective randomized multicenter study shows very rapid remission of ulcerative colitis by intensive granulocyte and monocyte adsorptive apheresis as compared with routine weekly treatment. Am J Gastroenterol (2009) 1.24
Comparison of the fecal microbiota profiles between ulcerative colitis and Crohn's disease using terminal restriction fragment length polymorphism analysis. J Gastroenterol (2011) 1.23
Usefulness of biodegradable stents constructed of poly-l-lactic acid monofilaments in patients with benign esophageal stenosis. World J Gastroenterol (2007) 1.22
Mucosal cytokine network in inflammatory bowel disease. World J Gastroenterol (2008) 1.19
The use of short-course zidovudine to prevent perinatal transmission of human immunodeficiency virus in rural Kenya. Am J Trop Med Hyg (2003) 1.16
Cross-sectional imaging in Crohn disease. Radiographics (2004) 1.15
Role of dietary fiber and short-chain fatty acids in the colon. Curr Pharm Des (2003) 1.14
Interleukin-32 expression in the pancreas. J Biol Chem (2009) 1.14
The S1P receptor modulator FTY720 prevents the development of experimental colitis in mice. Oncol Rep (2006) 1.13
Colonic subepithelial myofibroblasts in mucosal inflammation and repair: contribution of bone marrow-derived stem cells to the gut regenerative response. J Gastroenterol (2005) 1.12
Spectra of functional gastrointestinal disorders diagnosed by Rome III integrative questionnaire in a Japanese outpatient office and the impact of overlapping. J Gastroenterol Hepatol (2010) 1.09
Reduced Abundance of Butyrate-Producing Bacteria Species in the Fecal Microbial Community in Crohn's Disease. Digestion (2016) 1.09
Terminal restriction fragment length polymorphism analysis of the diversity of fecal microbiota in patients with ulcerative colitis. Inflamm Bowel Dis (2007) 1.09
Germinated barley foodstuff prolongs remission in patients with ulcerative colitis. Int J Mol Med (2004) 1.08
Newly developed biodegradable stents for benign gastrointestinal tract stenoses: a preliminary clinical trial. Digestion (2007) 1.07
Inflammatory responses induced by interleukin-17 family members in human colonic subepithelial myofibroblasts. J Gastroenterol (2007) 1.07
Recent advances in molecular approaches to gut microbiota in inflammatory bowel disease. Curr Pharm Des (2009) 1.06
Comparison of imatinib, dasatinib, nilotinib and INNO-406 in imatinib-resistant cell lines. Leuk Res (2008) 1.06
IL-17 selectively down-regulates TNF-alpha-induced RANTES gene expression in human colonic subepithelial myofibroblasts. J Immunol (2002) 1.05
Regulation of IL-11 expression in intestinal myofibroblasts: role of c-Jun AP-1- and MAPK-dependent pathways. Am J Physiol Gastrointest Liver Physiol (2003) 1.04
Regulation of amphiregulin and epiregulin expression in human colonic subepithelial myofibroblasts. Int J Mol Med (2006) 1.02
Re-evaluation of histogenesis of gastric carcinomas: a comparative histopathological study between Helicobacter pylori-negative and H. pylori-positive cases. Dig Dis Sci (2008) 1.02
A phase II trial of a selective c-Met inhibitor tivantinib (ARQ 197) monotherapy as a second- or third-line therapy in the patients with metastatic gastric cancer. Invest New Drugs (2013) 1.01
Modification of intestinal flora in the treatment of inflammatory bowel disease. Curr Pharm Des (2003) 1.00
Emergence of antiretroviral therapy resistance-associated primary mutations among drug-naive HIV-1-infected individuals in rural western Cameroon. J Acquir Immune Defic Syndr (2006) 1.00
The multidrug-resistance protein 4 polymorphism is a new factor accounting for thiopurine sensitivity in Japanese patients with inflammatory bowel disease. J Gastroenterol (2010) 1.00
Neutralization of complement component C5 ameliorates the development of dextran sulfate sodium (DSS)-colitis in mice. J Clin Biochem Nutr (2012) 0.99
Clinical utility of newly developed immunoassays for serum concentrations of adalimumab and anti-adalimumab antibodies in patients with Crohn's disease. J Gastroenterol (2013) 0.99
Energy metabolism in Japanese patients with Crohn's disease. J Clin Biochem Nutr (2009) 0.97
Interleukin-33 suppresses Notch ligand expression and prevents goblet cell depletion in dextran sulfate sodium-induced colitis. Int J Mol Med (2011) 0.97
RANTES -28G delays and DC-SIGN - 139C enhances AIDS progression in HIV type 1-infected Japanese hemophiliacs. AIDS Res Hum Retroviruses (2007) 0.96
S-1 monotherapy as second-line treatment for advanced pancreatic cancer after gemcitabine failure. Jpn J Clin Oncol (2010) 0.96
Phosphatidylinositol 3-kinase/Akt signaling mediates interleukin-32alpha induction in human pancreatic periacinar myofibroblasts. Am J Physiol Gastrointest Liver Physiol (2008) 0.96
Treatment of ulcerative colitis patients by long-term administration of germinated barley foodstuff: multi-center open trial. Int J Mol Med (2003) 0.95
Elevated circulating platelet-derived microparticles in patients with active inflammatory bowel disease. Am J Gastroenterol (2005) 0.95
Weekly paclitaxel for heavily treated advanced or recurrent gastric cancer refractory to fluorouracil, irinotecan, and cisplatin. Gastric Cancer (2010) 0.95
Development of a new immunoassay for the accurate determination of anti-infliximab antibodies in inflammatory bowel disease. J Gastroenterol (2011) 0.94
Relationship between serum infliximab trough levels and endoscopic activities in patients with Crohn's disease under scheduled maintenance treatment. J Gastroenterol (2013) 0.94
Expression of IL-24, an activator of the JAK1/STAT3/SOCS3 cascade, is enhanced in inflammatory bowel disease. J Immunol (2009) 0.94
Eubacterium limosum ameliorates experimental colitis and metabolite of microbe attenuates colonic inflammatory action with increase of mucosal integrity. World J Gastroenterol (2006) 0.94
Serum selenoprotein-P levels in patients with inflammatory bowel disease. Nutrition (2005) 0.94
Microsatellite instability with promoter methylation and silencing of hMLH1 can regionally occur during progression of gastric carcinoma. Cancer Lett (2010) 0.93